Literature DB >> 16794366

Value of routine measurement of serum calcitonin concentrations in patients with nodular thyroid disease: A multicenter study.

G Papi1, S M Corsello, K Cioni, A M Pizzini, S Corrado, C Carapezzi, G Fadda, A Baldini, C Carani, A Pontecorvi, E Roti.   

Abstract

BACKGROUND: The routine measurement of serum calcitonin (CT) has been proposed for patients with nodular thyroid disease (NTD), to detect unsuspected medullary thyroid carcinoma (MTC) before surgery.
OBJECTIVE: To assess the prevalence of hypercalcitoninemia and MTC in NTD patients; to compare the ability of CT measurement and fine needle aspiration cytology (FNAC) to predict MTC; to identify age groups of NTD patients who should be better candidates than others to undergo routine measurement of CT. PATIENTS AND METHODS: 1425 consecutive patients, referred from April 1, 2003, through March 31, 2004, to four Italian endocrine centers due to NTD, were grouped depending on age, and underwent basal and, in some cases, pentagastrin (Pg)-stimulated CT measurement, FNAC and, when indicated, surgery. Serum CT concentrations were measured by an immunoluminometric assay (ILMA).
RESULTS: Hypercalcitoninemia was found in 23 out of 1425 patients. MTC was discovered in 9 patients, all >40 yr old and showing high CT levels. Sensitivity of basal and Pg-stimulated CT to predict MTC before surgery was 100% for both tests, whereas specificity was 95 and 93%, respectively. CT specificity reached 100% when a cutoff value of 20 pg/ml was taken. FNAC showed an overall 86% sensitivity. When >10 mm MTC nodules were considered, FNAC sensitivity approached 100%. On the contrary, a correct cytological diagnosis was obtained in only one out of five patients with <10 mm MTC nodules (microMTC); in one patient with histologically proved microMTC, FNAC even demonstrated a benign lesion. Hypercalcitoninemia or MTC were associated with chronic thyroiditis in 30 or 33% of cases, respectively. C-cell hyperplasia was found in 57% of hypercalcitoninemic patients without MTC.
CONCLUSIONS: Basal CT measurement detects elevated CT values in 1.6% of NTD patients. Although CT is not a specific marker of MTC, its routine measurement represents a useful tool in the pre-operative evaluation of NTD patients, particularly those >40 yr old presenting with nodules <10 mm, even when FNAC does not show malignant features. To our knowledge, this is the first trial using ILMA to assess the ability of pre-operative CT measurement to predict MTC in a large series of NTD patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16794366     DOI: 10.1007/BF03344126

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  37 in total

Review 1.  The calcitonin conundrum--is it time for routine measurement of serum calcitonin in patients with thyroid nodules?

Authors:  Steven P Hodak; Kenneth D Burman
Journal:  J Clin Endocrinol Metab       Date:  2004-02       Impact factor: 5.958

2.  Should serum calcitonin be routinely measured in patients with thyroid nodules--will the law answer before endocrinologists do?

Authors:  L J Deftos
Journal:  J Clin Endocrinol Metab       Date:  2004-09       Impact factor: 5.958

Review 3.  Seminars in medicine of the Beth Israel Hospital, Boston. The RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirschsprung's disease.

Authors:  C Eng
Journal:  N Engl J Med       Date:  1996-09-26       Impact factor: 91.245

4.  Usefulness of fine-needle aspiration in the diagnosis of thyroid carcinoma: a retrospective study in 37,895 patients.

Authors:  C Ravetto; L Colombo; M E Dottorini
Journal:  Cancer       Date:  2000-12-25       Impact factor: 6.860

5.  Symptomatic C-cell hyperplasia associated with chronic lymphocytic thyroiditis.

Authors:  P W Biddinger; M F Brennan; P P Rosen
Journal:  Am J Surg Pathol       Date:  1991-06       Impact factor: 6.394

6.  Age-associated C-cell hyperplasia in the human thyroid.

Authors:  W G Gibson; T C Peng; B P Croker
Journal:  Am J Pathol       Date:  1982-03       Impact factor: 4.307

Review 7.  Surgical strategy for the treatment of medullary thyroid carcinoma.

Authors:  J B Fleming; J E Lee; M Bouvet; P N Schultz; S I Sherman; R V Sellin; K E Friend; M A Burgess; G J Cote; R F Gagel; D B Evans
Journal:  Ann Surg       Date:  1999-11       Impact factor: 12.969

Review 8.  Thyroid cytology and histology.

Authors:  Y C Oertel; J E Oertel
Journal:  Baillieres Best Pract Res Clin Endocrinol Metab       Date:  2000-12

9.  C-cell hyperplasia associated with chronic lymphocytic thyroiditis: a retrospective quantitative study of 112 cases.

Authors:  S Guyetant; N Wion-Barbot; M C Rousselet; B Franc; J C Bigorgne; J P Saint-Andre
Journal:  Hum Pathol       Date:  1994-05       Impact factor: 3.466

10.  Cancer risks in patients with chronic lymphocytic thyroiditis.

Authors:  L E Holm; H Blomgren; T Löwhagen
Journal:  N Engl J Med       Date:  1985-03-07       Impact factor: 91.245

View more
  13 in total

Review 1.  Determination of calcitonin levels in C-cell disease: clinical interest and potential pitfalls.

Authors:  Giuseppe Costante; Cosimo Durante; Zélia Francis; Martin Schlumberger; Sebastiano Filetti
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2009-01

Review 2.  [Calcitonin determination for early diagnosis of medullary thyroid cancer].

Authors:  W Karges
Journal:  Chirurg       Date:  2010-07       Impact factor: 0.955

3.  Development and application of a novel sensitive immunometric assay for calcitonin in a large cohort of patients with medullary and differentiated thyroid cancer, thyroid nodules, and autoimmune thyroid diseases.

Authors:  Cléber P Camacho; Susan C Lindsey; Teresa S Kasamatsu; Alberto L Machado; João Roberto M Martins; Rosa Paula M Biscolla; Magnus R Dias da Silva; José Gilberto H Vieira; Rui M B Maciel
Journal:  Eur Thyroid J       Date:  2014-06-18

4.  Calcitonin Levels in Thyroid Disease Are Not Affected by Autoimmune Thyroiditis or Differentiated Thyroid Carcinoma.

Authors:  Fabio Maino; Cristina Dalmiglio; Nicoletta Benenati; Michele Campanile; Tania Pilli; Raffaella Forleo; Lucia Brilli; Cristina Ciuoli; Silvia Cantara; Marco Capezzone; Alessandra Cartocci; Furio Pacini; Maria Grazia Castagna
Journal:  Eur Thyroid J       Date:  2020-10-12

5.  Timing and extent of thyroid surgery for gene carriers of hereditary C cell disease--a consensus statement of the European Society of Endocrine Surgeons (ESES).

Authors:  Bruno Niederle; Frédéric Sebag; Michael Brauckhoff
Journal:  Langenbecks Arch Surg       Date:  2013-12-03       Impact factor: 3.445

6.  Ultrasonographic findings of medullary thyroid carcinoma: a comparison with papillary thyroid carcinoma.

Authors:  Sung-Hun Kim; Bum-Soo Kim; So-Lyung Jung; Jung-Whee Lee; Po-Sung Yang; Bong-Joo Kang; Hyun-Wook Lim; Jee-Young Kim; In-Yong Whang; Heuk-Sang Kwon; Chan-Kwon Jung
Journal:  Korean J Radiol       Date:  2009-03-03       Impact factor: 3.500

Review 7.  Is Hashimoto's thyroiditis a risk factor for medullary thyroid carcinoma? Our experience and a literature review.

Authors:  Ayman A Zayed; Moaath K Mustafa Ali; Omar I Jaber; Moh'd J Suleiman; Ashraf A Ashhab; Wajdi Mohammed Al Shweiat; Munther Suliaman Momani; Maha Shomaf; Salah Mohammed AbuRuz
Journal:  Endocrine       Date:  2014-07-24       Impact factor: 3.633

8.  Calcitonin testing for detection of medullary thyroid cancer in people with thyroid nodules.

Authors:  Hans Hg Verbeek; Jan Willem B de Groot; Wim J Sluiter; Anneke C Muller Kobold; Edwin R van den Heuvel; John Tm Plukker; Thera P Links
Journal:  Cochrane Database Syst Rev       Date:  2020-03-16

Review 9.  Evidence-based approach to the management of sporadic medullary thyroid carcinoma.

Authors:  Jeffrey F Moley; Elizabeth A Fialkowski
Journal:  World J Surg       Date:  2007-05       Impact factor: 3.352

10.  Twenty years of experience with the preoperative diagnosis of medullary cancer in a moderately iodine-deficient region.

Authors:  Tamas Solymosi; Gyula Lukacs Toth; Dezso Nagy; Istvan Gal
Journal:  Int J Endocrinol       Date:  2013-03-06       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.